In a sector note on U.S. Medical Supplies and Devices, UBS analyst Danielle Antalffy initiated coverage of DexCom with a Buy rating and $142 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- DexCom Q1 report can be a catalyst for shares, says Jefferies
- DexCom announces expanded coverage for G6 CGM System in Manitoba
- DexCom has no material exposure to developments at Silicon Valley Bank
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
- BofA says buy DexCom on weakness after Abbott’s Libre gets pump integration